Suppr超能文献

药物治疗与血运重建治疗冠状动脉慢性完全闭塞患者的两年临床结局比较

Two-year clinical outcomes of medical therapy vs. revascularization for patients with coronary chronic total occlusion.

机构信息

Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian City, China.

Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian City, China.

出版信息

Hellenic J Cardiol. 2020 Jul-Aug;61(4):264-271. doi: 10.1016/j.hjc.2019.03.006. Epub 2019 Apr 3.

Abstract

OBJECTIVES

There are little data on the long-term clinical outcomes of medical therapy (MT) compared with revascularization in patients with chronic total occlusions (CTOs).

METHODS

Between January 2007 and December 2016, a total of 1655 patients with ≥1 CTO were enrolled in our center and were divided into the MT group (n = 800) and revascularization group (n = 855) according to the initial treatment strategy. Propensity score matching was also performed to adjust for baseline characteristics. The primary outcome was cardiac death.

RESULTS

After 2 years of follow-up, there was no significant difference between the two groups with regard to the prevalence of cardiac death (MT vs. revascularization: 6.6% vs. 4.2%, adjusted hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.60-1.49, p = 0.820). In the propensity-matched population (406 pairs), there were no significant differences in the prevalence of cardiac death (MT vs. revascularization: 5.4% vs. 4.7%, HR 0.88, 95% CI 0.48-1.63, p = 0.694), except for target vessel revascularization (TVR) (0.44, 0.31-0.63, <0.001) and major adverse cardiovascular events (MACE) (0.51, 0.38-0.68, <0.001), between the two groups. There were also no significant differences in the prevalence of cardiac death (MT vs. successful CTO-PCI: 6.6% vs. 4.0%, HR 0.94, 95% CI 0.41-2.15, p = 0.881) between the MT and successful CTO-PCI groups.

CONCLUSION

As an initial management strategy in patients with CTOs, revascularization did not reduce the risk of cardiac death compared with treatment with medical therapy alone. However, revascularization was associated with reduction in the prevalence of TVR and MACE. Furthermore, successful CTO-PCI was also not associated with improved long-term survival compared with MT alone.

摘要

目的

与血运重建相比,关于慢性完全闭塞病变(CTO)患者的药物治疗(MT)长期临床结局的数据较少。

方法

2007 年 1 月至 2016 年 12 月,共有 1655 名符合至少 1 处 CTO 的患者纳入本中心,根据初始治疗策略分为 MT 组(n=800)和血运重建组(n=855)。还进行了倾向评分匹配以调整基线特征。主要结局是心源性死亡。

结果

随访 2 年后,两组心源性死亡发生率无显著差异(MT 组与血运重建组:6.6% vs. 4.2%,校正后的风险比[HR]0.95,95%置信区间[CI]0.60-1.49,p=0.820)。在倾向评分匹配人群(406 对)中,心源性死亡发生率也无显著差异(MT 组与血运重建组:5.4% vs. 4.7%,HR 0.88,95% CI 0.48-1.63,p=0.694),但靶血管血运重建(TVR)(0.44,0.31-0.63,<0.001)和主要不良心血管事件(MACE)(0.51,0.38-0.68,<0.001)除外。MT 组与 CTO-PCI 成功组之间心源性死亡发生率也无显著差异(MT 组:6.6% vs. CTO-PCI 成功组:4.0%,HR 0.94,95% CI 0.41-2.15,p=0.881)。

结论

作为 CTO 患者的初始治疗策略,与单独药物治疗相比,血运重建并未降低心源性死亡风险。然而,血运重建与降低 TVR 和 MACE 发生率相关。此外,与单独 MT 相比,成功的 CTO-PCI 也不能改善长期生存率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验